Check out the following recent activity in the biopharma funding space. Take a closer look at 43 notable updates for this week:
Want to get this list of recently funded companies and more data? Fill out a quote request to get more info or set up a call (Quote Request Form)
– Private Funding –
Surrozen
💸 Entered into a $192.5M private placement to fund the SZN-043 clinical development program.
Obsidian Therapeutics
💸 Raised $160.5M Series C financing led Wellington Management and will go towards enrolling more patients for its OBX-115 drug trial for NSCLC.
ImmPACT Bio USA Inc.
💸 $141.7M offering w/ $139.8M already sold.
Alterome Therapeutics
💸 Raised $132M in Series B financing led by Goldman Sachs Alternatives to advance the development of the AKT1 E17K & KRAS selective inhibitor candidates.
Diagonal Therapeutics
💸 Launched w/ $128M in financing to pioneer a new approach to discovering and developing agonist antibodies.
ImmunoGenesis, Inc.
💸 $66.5M offering w/ $44.4M already sold.
Neurosterix
💸 Launched w/ $63M funding to advance allosteric modulator therapeutics (e.g., M4 PAM) for neurological disorders.
Biolinq
💸 Raised $58M in funding led by Alpha Wave Ventures to support the completion pivotal trial this year, proprietary intradermal glucose sensor evaluation, and subsequent FDA submission.
Selux Diagnostics
💸 Raised an additional $48M in funding to launch their next phase of commercialization of the Selux Next Generation Phenotyping (NGP) system within the US.
Protara Therapeutics
💸 Entered into an oversubscribed $45M private placement financing to fund the company into 2026.
EnteroBiotix
💸 Completed £27M ($34M) funding round supported by various investors to advance EBX-102-02 through a Ph2 trial treating IBS and also to other drug pipelines.
Melt Pharmaceuticals
💸 Closed $24M Series B funding from various investors to further the development of MELT-300.
Biofidelity
💸 Raised $24M financing to accelerate commercialization of ASPYRE®-Lung novel test for NSCLC in the US.
Miach Orthopaedics
💸 Raised $20M in Series B extension funding to support commercial expansion and clinical activities for the BEAR implant for anterior cruciate ligament (ACL) tears.
iBio, Inc.
💸 $15M equity financing
Delphinus Medical Technologies, Inc.
💸 $15M debt financing w/ $5.2M already sold.
Delova Biotech
💸 Completed >100M CNY ($14M) in Series B+ financing led by several investors
UniXell Biotechnology
💸 Completed >100M CNY ($14M) in Series A financing led by Tasly Capital to accelerate the clinical research pipeline and support the industrialization of innovative cell therapy drugs.
Conformation-X Therapeutics
💸 Secured $13.5M in funding to advance its immune-oncology pipeline.
AI Proteins, Inc.
💸 $10M debt financing w/ $4.9M already sold.
Carmell Corp.
💸 Announces $3M private placement.
Mach5 Therapeutics, Inc.
💸 $2.9M offering w/ $2.6M already sold.
Mercury Bio, Inc.
💸 $2M offering w/ $149.9K already sold.
Juniper Biomedical
💸 Secured $2M Series Seed funding led by Auroral Holdings and $1M through the NIH SPARC Neuromod prize to accelerate development in the pelvic health disorders space.
Precision Epigenomics Inc
💸 $1.7M offering w/ $1.1M already sold.
Anchor Balloon, Inc.
💸 $1.5M debt financing.
BetterLife
💸 Closed $1.168M convertible debentures to further advance IND-enabling studies of its non-hallucinogenic LSD-based candidate, BETR-001.
Medibiofarma
💸 Closed €1M ($1M) financing round to further the clinical phase of MBF-118, MBF-015, and MBF-362.
Ironic Biotech
💸 Raised €1M ($1M) led by Nordic Foodtech VC to develop interventions for both iron deficiency and anemia.
Cessation Therapeutics
💸 $1M offering.
Addiction Cure Therapeutic Sciences Inc
💸 $1M offering.
Bio-Path Holdings, Inc.
💸 $317K warranted option.
Gemina Laboratories Ltd.
💸 $302K debt financing.
Sirona Biochem
💸 Closed CAD 132K ($97K) of private placement to be used for general working capital.
Swan NeuroTech, Inc.
💸 $95K debt financing
– Post-IPO/Public Funding –
Rhythm Pharmaceuticals
💸 Sold $150M in Series A convertible preferred stock in a financing led by Perceptive Advisors, LLC. The financing extends its cash runway into 2026, enabling a topline data readout from its Ph3 trial in hypothalamic obesity in H1 2025.
Gritstone bio
🏦 $32M public offering.
Sutro Biopharma
🏦 $7M underwritten offering.
BioLineRx
🏦 $6M registered direct offering.
Biora Therapeutics
🏦 $6M registered direct offering.
Matinas BioPharma
🏦 $10M registered direct offering.
SINTX Technologies
🏦 $1.5M public offering.
RedHill Biopharma
🏦 $1.25M registered direct offering.
FIG. 1. Recent Biotech Funding Activity
FIG. 2. Public Funding per Disease Category for Apr 1-5 Public Company Funding Events
---
Article History:
RF, DV (04/09/24)
コメント